Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, 98125 Messina, Italy.
J Neuroinflammation. 2012 Apr 26;9:81. doi: 10.1186/1742-2094-9-81.
Statins such as simvastatin are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase used in the prevention of cardiovascular disease. In addition to their cholesterol-lowering activities, statins exert pleiotropic anti-inflammatory effects, which might contribute to their beneficial effects on lipid-unrelated inflammatory diseases. Recently it has been demonstrated that the peroxisome proliferator-activated receptor (PPAR)-α mediates anti-inflammatory effects of simvastatin in vivo models of acute inflammation. Moreover, previous results suggest that PPAR-α plays a role in control of secondary inflammatory process associated with spinal cord injury (SCI).
With the aim to characterize the role of PPAR-α in simvastatin activity, we tested the efficacy of simvastatin (10 mg/kg dissolved in saline i.p. 1 h and 6 h after the trauma) in an experimental model of SCI induced in mice by extradural compression of the spinal cord (T6-T7 level) using an aneurysm clip with a closing force of 24 g via a four-level T5-T8 laminectomy, and comparing mice lacking PPAR-α (PPAR-α KO) with wild type (WT) mice. In order to elucidate whether the effects of simvastatin are due to activation of the PPAR-α, we also investigated the effect of a PPAR-α antagonist, GW6471 (1 mg/kg administered i.p. 30 min prior treatment with simvastatin) on the protective effects of on simvastatin.
Results indicate that simvastatin activity is weakened in PPAR-α KO mice, as compared to WT controls. In particular, simvastatin was less effective in PPAR-α KO, compared to WT mice, as evaluated by inhibition of the degree of spinal cord inflammation, neutrophil infiltration, nitrotyrosine formation, pro-inflammmatory cytokine expression, nuclear factor (NF)-κB activation, inducible nitric-oxide synthase (iNOS) expression, and apoptosis. In addition we demonstrated that GW6471 significantly antagonized the effect of the statin and thus abolished the protective effect.
This study indicates that PPAR-α can contribute to the anti-inflammatory activity of simvastatin in SCI.
辛伐他汀等他汀类药物是 3-羟基-3-甲基戊二酰辅酶 A(HMG-CoA)还原酶的抑制剂,用于预防心血管疾病。除了降低胆固醇的作用外,他汀类药物还具有多效抗炎作用,这可能有助于它们对与脂质无关的炎症性疾病产生有益影响。最近已经证明,过氧化物酶体增殖物激活受体(PPAR)-α在体内急性炎症模型中介导辛伐他汀的抗炎作用。此外,先前的结果表明,PPAR-α在控制与脊髓损伤(SCI)相关的继发性炎症过程中发挥作用。
为了研究 PPAR-α在辛伐他汀活性中的作用,我们在通过 T5-T8 椎板切除术进行四级 T5-T8 椎板切除术,使用闭合力为 24g 的动脉瘤夹对脊髓(T6-T7 水平)进行硬膜外压迫诱导的 SCI 实验模型中,测试了辛伐他汀(10mg/kg 在创伤后 1 小时和 6 小时溶于生理盐水中腹腔注射)的疗效,并将缺乏 PPAR-α 的小鼠(PPAR-α KO)与野生型(WT)小鼠进行比较。为了阐明辛伐他汀的作用是否归因于 PPAR-α 的激活,我们还研究了 PPAR-α 拮抗剂 GW6471(辛伐他汀治疗前 30 分钟腹腔注射 1mg/kg)对辛伐他汀保护作用的影响。
结果表明,与 WT 对照组相比,辛伐他汀在 PPAR-α KO 小鼠中的活性减弱。具体而言,与 WT 小鼠相比,辛伐他汀在 PPAR-α KO 小鼠中的作用较弱,如通过抑制脊髓炎症程度、中性粒细胞浸润、硝基酪氨酸形成、促炎细胞因子表达、核因子(NF)-κB 激活、诱导型一氧化氮合酶(iNOS)表达和细胞凋亡来评估。此外,我们证明 GW6471 可显著拮抗他汀类药物的作用,从而消除其保护作用。
本研究表明,PPAR-α 可有助于辛伐他汀在 SCI 中的抗炎作用。